3rd Generation - ESC

In south east Asia, Embryonic stem cell therapy took stage at around year 2010. This was the early stages of practice using Pluripotent cells to reduce symptoms of premature ageing and chronic degenerative diseases. These extremely young and active cellular materials are procured from early embryos from specially bred sheep (formed at the very beginning of life) to trigger efficient rejuvenation and regeneration of the human body.

Upon procurement, these embryonic stem cells undergo a rigorous and complex series of processes, from high tech filtration under stringent conditions, to cryogenic activity and lyophilising** to preserve the biological composition and integrity of the cells. The lyophilised** embryonic stem cells then can be securely transported around the world and reactivated again through reconstitution (where the lyophilised cells are hydrated with sterilised water).

Embryonic stem cells are Pluripotent (the ability of continuous cell renewal a.k.a. Regeneration), that is, they are able to differentiate into all derivatives of the three primary germ layers: ectoderm, endoderm, and mesoderm – together they can regenerate most body systems in the adult body.

However, there are 2 major concerns around the world with regards to ESCs.

ESCs are prone to immunorejection by the body, and therefore are possibly less effective*
The ethical controversy (inhumane) of embryo destruction associated with ESC procurement*

* Referenced from NIH-PA Author Manuscript
Vet Clin North Am Equine Pract. 2011 August ; 27(2): 233–242. doi:10.1016/j.cveq.2011.04.003.

** This lyophilisation of ESCs factors to date is an exclusive and patented cell preservation technology. This advanced standard of technology has successfully allowed cell therapy to be readily available, superseding older techniques such as ‘Frozen cells’, which is temperature sensitive, risking the integrity of cells.